Automate Your Wheel Strategy on TOVX
With Tiblio's Option Bot, you can configure your own wheel strategy including TOVX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol TOVX
- Rev/Share 0.0228
- Book/Share 1.5731
- PB 0.2667
- Debt/Equity 0.1179
- CurrentRatio 1.1895
- ROIC -0.8656
- MktCap 4026340.0
- FreeCF/Share -2.6785
- PFCF -0.2226
- PE -0.0959
- Debt/Assets 0.0349
- DivYield 0
- ROE -1.6932
- Rating B-
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 5
- P/B Score 4
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Theriva™ Biologics Reports Second Quarter 2025 Operational Highlights and Financial Results
TOVX
Published: August 11, 2025 by: GlobeNewsWire
Sentiment: Neutral
Published: August 11, 2025 by: GlobeNewsWire
Sentiment: Neutral
- Released positive topline data from the VIRAGE Phase 2b study of VCN-01 (zabilugene almadenorepvec); expanded data to be presented at the European Society for Medical Oncology (ESMO) 2025 Congress in October -
Read More
About Theriva Biologics, Inc. (TOVX)
- IPO Date 2006-12-18
- Website https://therivabio.com
- Industry Biotechnology
- CEO Steven A. Shallcross CPA
- Employees 20
Theriva Biologics Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. It also develops VCN-01 for the treatment of patients with pancreatic cancer, head and neck squamous cell carcinoma, colorectal cancer, and retinoblastoma. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics; SYN-005 for the prevention and treatment of pertussis; and VCN-11 to treat cancer. It has collaborations with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. The company was formerly known as Synthetic Biologics, Inc. and changed its name to Theriva Biologics Inc. in October 2022. Theriva Biologics Inc. is headquartered in Rockville, Maryland.